PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA
Tovah A. Day(Boston University), David M. Weinstock(Broad Institute)
Cited by 41
Related Papers
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
|The Lancet Oncology|2015|613
The promise of organ and tissue preservation to transform medicine
|Nature Biotechnology|2017|530
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
|Journal of Clinical Oncology|2016|187
Targeting minimal residual disease: a path to cure?
|Nature reviews. Cancer|2018|164
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
|The Journal of Experimental Medicine|2012|162